Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

JD.com's Stub Trading Cheapish Ahead Of Logistics Spin-Off

JD Logistics (2618 HK): Priced Towards The Low End

Quiddity Advisors

Equity Bottom-Up

<div>
<p><em>This week in StubWorld ...</em></p>
<p><a href="https://www.smartkarma.com/entities/jd-health-international" target="_blank" data-smartkarma-citation="entities:29677:1" rel="noopener">JD Health (6618 HK)</a> was listed on the 8 December at an IPO price of <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2020/1207/9539949/2020120700123.pdf" target="_blank" rel="noopener">HK$70.58</a>, towards the top-end of its price range, and has traded up ~88% to HK$132.50/share, with a current market cap of US$52.7bn. </p>
</div>
<div>
<p>JDH is the spin-off of <a href="https://www.smartkarma.com/entities/jd-com-inc" target="_blank" data-smartkarma-citation="entities:29043:1" rel="noopener">JD.com (HK) (9618 HK)</a> / <a href="https://www.smartkarma.com/entities/jd-com-inc-adr" target="_blank" data-smartkarma-citation="entities:446:1" rel="noopener">JD.com Inc (ADR) (JD US)</a>, which owns <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2020/1208/2020120800216.pdf" target="_blank" rel="noopener">68.73%</a> in JDH after the IPO, down from 81.04% pre-IPO.</p>
<p>That stake is worth US$36.5bn, or around 30% of its current market cap, therefore this is not a super strong parent/subsidiary relationship. </p>
<p>Yet the implied stub is trading at a not-undemanding forward PER of 34x, for a company with a three-year net profit CAGR of 44%.</p>
</div>
<div>
<div>
<hr>
<p>Preceding my comments on JD.com are the weekly setup/unwind tables for Asia-Pacific Holdcos.</p>
</div>
<div>
<p>These relationships trade with a minimum liquidity threshold of US$1mn on a 90-day moving average, and a % market capitalisation threshold - the $ value of the holding/opco held, over the parent’s market capitalisation, expressed in percent - of at least 20%.</p>
</div>
</div>


This week in StubWorld ...
JD Health (6618 HK) was listed on the 8 December at an IPO price of HK$70.58, towards the top-end of its price range, and has traded up ~88% to HK$132.50/share, with a current market cap of US$52.7bn. 


JDH is the spin-off of JD.com (HK) (9618 HK) / JD.com Inc (ADR) (JD US), which owns 68.73% in JDH after the IPO, down from 81.04% pre-IPO.
That stake is worth US$36.5bn, or around 30% of its current market cap, therefore this is not a super strong parent/subsidiary relationship. 
Yet the implied stub is trading at a not-undemanding forward PER of 34x, for a company with a three-year net profit CAGR of 44%.




Preceding my comments on JD.com are the weekly setup/unwind tables for Asia-Pacific Holdcos.


These relationships trade with a minimum liquidity threshold of US$1mn on a 90-day moving average, and a % market capitalisation threshold - the $ value of the holding/opco held, over the parent’s market capitalisation, expressed in percent - of at least 20%.



JD.com

StubWorld: JD.com In JD Health's Shadow